Euro

Evra: combined contraceptive drug

Evra is a combined contraceptive drug developed for use by women. It is manufactured by the German pharmaceutical group, Janssen-Cilag/Lohmann Therapeutic Systems, and contains a combination of the hormones ethinyl estradiol and norelgestromin.

Evra is a transdermal therapeutic system that releases 150 mcg of norelgestromin and 20 mcg of ethinyl estradiol over 24 hours. Each system contains 6 mg norelgestromin and 600 mcg ethinyl estradiol.

Women can use Evra as a contraceptive. The drug can only be used after consultation with a doctor and a prescription. Evra is not recommended for women who suffer from certain diseases or have special health conditions.

Contraindications to the use of Evra may include hypersensitivity to the components of the drug, venous thrombosis, arterial thrombosis, as well as the presence of serious risk factors for arterial thrombosis. In addition, Evra is not recommended in the presence of certain diseases, such as migraine with aura, breast cancer or estrogen-dependent tumors, liver adenoma and carcinoma, genital bleeding, as well as during lactation and the postpartum period.

Side effects from Evra may include headache, nausea, vomiting, weight changes, mood changes, and changes in menstrual cycles. Rare but serious side effects such as blood clots and strokes are also possible.

Despite possible side effects, Evra can be an effective contraceptive for women who want to avoid pregnancy. However, before you start using Evra, you must consult your doctor and carefully study the instructions for use.